The outcome of ambulatory XXXX management using a multidisciplinary approach.

@entity1 @entity548 @entity23294 @entity1150 @entity1031 @entity204
Low molecular weight heparins (LMWHs) have been demonstrated to be at least as safe and effective as unfractionated heparin (UFH) in the initial management of @entity1150 ( @entity1150 ). However, the effectiveness of using LMWH in the ambulatory management of @entity1150 in a 'real-life' setting has yet to be evaluated. This multicentre retrospective study involving 697 @entity1 considers the outcome data of @entity1 under- going ambulatory @entity1150 treatment with @entity23294 (Innohep(R), Leo Pharmaceuticals, Risborough, Buckinghamshire, UK). During the 6 months following presentation, 17 (2.5%) @entity1 had confirmed @entity1031 complications, of which 14 occurred subsequent to the initial LMWH treatment phase ('late'). There were no deaths in this group. Bleeding complications were reported in 23 (3.4%) @entity1 , with 13 of these being classified as 'late'. Of these, two events were considered major resulting in hospitalization and @entity204 . Hospitalization for all causes was 6.8% (45 @entity1 ) with 32 @entity1 being admitted for @entity1031 or @entity548 complications. Overall mortality was 6.7%. These results compare favourably with published clinical trial data. This study demonstrates that ambulatory treatment of proven @entity1150 with LMWH is both safe and effective.
